Colestilan for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis.

Colestilan for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Expert Rev Endocrinol Metab. 2015 Mar;10(2):131-142 Authors: Locatelli F, Dimkovic N, Spasovski G Abstract Chronic kidney disease in the later stages poses many treatment challenges. Hyperphosphatemia is one that is well-known and is often linked to increased cardiovascular morbidity/mortality. Currently, a number of phosphate binders are available that act to conserve serum phosphate at normal or near normal levels. However, it is the overall profile of all binders that needs to be taken into account and the risks and the potential benefits associated with each agent must be balanced when selecting a particular phosphate binder. It is known that calcium-based binders, although effective phosphate binders, may lead to hypercalcemia and/or positive calcium balance and cardiovascular calcification. One, new non-calcium phosphate binder, recently approved in Europe, is colestilan. Colestilan possesses a range of properties that may afford further advantages over simply reducing serum phosphate. This review assesses the pharmacology and clinical data of colestilan used to treat hyperphosphatemia in chronic kidney disease stage 5 patients on dialysis. The article was written based on literature searches using PubMed to find articles published on phosphate binders or colestilan over the last 10 years. PMID: 30293511 [PubMed]
Source: Expert Review of Endocrinology and Metabolism - Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research

Related Links:

Abstract OBJECTIVE: To report the spectrum of ethambutol induced optic neuropathy in a group of renal patients with tuberculosis and the role of visual evoked response (VER) in evaluating this disorder. METHODS: Twenty-three renal patients who were started on ethambutol as a part of anti-tubercular treatment for tuberculosis in India, were divided into 4 groups based on glomerular filtration rate (GFR): group 1-chronic kidney disease (CKD) with GFR 30 ≤ 60 mL/min; and group 4-GFR> 60
Source: Canadian Journal of Ophthalmology - Category: Opthalmology Authors: Tags: Can J Ophthalmol Source Type: research
Conclusions: Enarodustat corrected and maintained Hb levels in anemic patients with hemodialysis-dependent CKD. Phase 3 studies of enarodustat are currently ongoing.Nephron
Source: Nephron - Category: Urology & Nephrology Source Type: research
Authors: Marie Patrice H, Joiven N, Hermine F, Jean Yves B, Folefack François K, Enow Gloria A Abstract BACKGROUND: Late presentation (LP) of chronic kidney disease (CKD) patients to nephrologist is a serious problem worldwide with persistent high prevalence despite known benefits of early nephrology care. OBJECTIVE: Determine the prevalence and factors associated with LP of CKD patients to nephrologists in Cameroon. METHODS: A cross-sectional study from October 2015 to May 2016 at the nephrology units of the Douala General and Laquintinie hospitals, including all consenting incident CKD patients. Da...
Source: Renal Failure - Category: Urology & Nephrology Tags: Ren Fail Source Type: research
Conclusion: There was dose-related increase in Hb across all doses compared to placebo in mITT and per-protocol populations. Desidustat also increased pharmacokinetic parameters Cmax and AUC in dose-related manner. There was no significant change in vital signs, electrocardiographic parameters, or safety laboratory values. Clinical Trial Registration Number CTRI/2017/05/008534 (registered on May 11, 2017).Am J Nephrol 2019;49:470 –478
Source: American Journal of Nephrology - Category: Neurology Source Type: research
Publication date: Available online 20 May 2019Source: Pharmacological ResearchAuthor(s): C. Michael White, Vinay Pasupuleti, Yuani M. Roman, Yangzhou Li, Adrian V. HernandezAbstractTurmeric extract or active component curcumin may have anti-inflammatory effects in people with chronic inflammatory diseases. The effect of turmeric or curcumin on a wide range of inflammatory markers has not been evaluated in a systematic review. We performed a systematic review of randomized controlled trials (RCTs) evaluating the effects of oral turmeric or curcumin on inflammatory markers (CRP, hsCRP, IL-1, IL-6, TNF) in patients with a wid...
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
The Guatemalan Foundation for Children with Kidney Diseases was established in 2003 as the first and only comprehensive pediatric nephrology program and hemodialysis unit in Guatemala. Bridge of Life (BOL) is a not-for-profit charitable organization focused on chronic kidney disease and supplied equipment, training and support during formation of the hemodialysis unit. Pediatric permanent vascular access (VA) expertise had not been established and noncuffed dialysis catheters provided almost all VA, many through subclavian vein access sites.
Source: Journal of Vascular Surgery - Category: Surgery Authors: Source Type: research
In conclusion, in consensus with a recent systematic review, a single bout of the 60 J/arm was the best dose/response for increased strength of the small muscles (handgrip strength). In view of the increasing i mplementation of exercise programs during hemodialysis, the current study opens a new field for PBMT for CKD patients.
Source: Lasers in Medical Science - Category: Laser Surgery Source Type: research
ConclusionAlthough the progress of medical treatment is changing rapidly, surgical treatment is still an effective way to control serum iPTH and calcium chronically for SHPT patients. Complex SHPT patients can also receive satisfied effect by surgical treatment, without apparently increasing the risk of complications.
Source: American Journal of Otolaryngology - Category: Endocrinology Source Type: research
Iron parameters have not been well characterized in pre-dialysis patients with chronic kidney disease, and it remains unclear if abnormal iron balance is associated with increased mortality. Therefore, we performed a historical cohort study using data from the Veterans Affairs Corporate Data Warehouse to evaluate the relationship between iron status and mortality. We identified a pre-dialysis chronic kidney disease cohort with at least one set of iron indices between 2006-2015. The cohort was divided into four iron groups based on the joint quartiles of serum transferrin saturation (percent) and ferritin concentration (ng/...
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: Clinical Investigation Source Type: research
AbstractSecondary and tertiary hyperparathyroidism is an important problem of chronic kidney disease. Brown tumor is a benign, unusual, reactive lesion as a result of disturbed bone remodeling, from long-standing increase in parathyroid hormone level. Brown tumors may cause morbidity due to pressure symptoms on neural structures and spontaneous bone fractures. Herein, we presented a peritoneal dialysis patient with tertiary hyperparathyroidism under calcand calcitriol treatment for 4  years due to refusing of the parathyroidectomy operation. She admitted to hospital for sudden onset back pain with difficulty in gait a...
Source: CEN Case Reports - Category: Urology & Nephrology Source Type: research
More News: Calcium | Cardiology | Cardiovascular | Chronic Kidney Disease | Dialysis | Drugs & Pharmacology | Endocrinology | Heart | Urology & Nephrology